In , Swiss chemist Bernhard Joos set up a small research laboratory in Schaffhausen , Switzerland. In the early nineties, the marketing organizations of Cilag and Janssen Pharmaceutica were joined to form Janssen-Cilag. The non-marketing activities of both companies still operate under their original name.
Cilag continues to have operations under the Cilag name in Switzerland, ranging from research and development through manufacturing and international services. Janssen Pharmaceuticals can be traced back to In , Constant Janssen , the father of Paul Janssen, acquired the right to distribute the pharmaceutical products of Richter , a Hungarian pharmaceutical company, for Belgium, the Netherlands and Belgian Congo.
On 23 October , he founded the N. Produkten Richter in Turnhout. After the Second World War, the name for the company products was changed to Eupharma, although the company name Richter would remain until Paul Janssen founded his own research laboratory in on the third floor of the building in the Statiestraat, still within the Richter-Eurpharma company of his father.
Janssen named after Constant Janssen. On 2 May , the research department in Beerse became a separate legal entity, the N. Research Laboratorium C. On 10 February , the name was changed to Janssen Pharmaceutica N. Between and , Janssen Pharmaceuticals expanded worldwide, with the company growing in size to approximately employees worldwide. The research activities of the Janssen Research Foundation and the R. Johnson Pharmaceutical Research Institute were merged into the new global research organization. In August , the company acquired Aragon Pharmaceuticals, Inc..
In January , the company acquired Interventional Spine, Inc. Janssen Biotech, Inc. In , Centocor transitioned into a publicly traded company. In , Centocor, Inc. In June , Centocor Ortho Biotech acquired RespiVert, a privately held drug discovery company focused on developing small-molecule, inhaled therapies for the treatment of pulmonary diseases.
In , George F. Merson opened a facility in Edinburgh for the manufacturing, packaging and sterilizing of catgut, silk and nylon sutures. Merson's company in , and this was renamed Ethicon Suture Laboratories.
During the s, Ethicon diversified into new and advanced products and technologies and formed four different companies under the Ethicon umbrella, each of which specializes in different products. Ethicon Endo-Surgery was part of Ethicon Inc. In keeping with earlier agreements, the company announced its intention to delist Actelion, whilst spinning out its drug discovery operations and early-stage clinical development assets into a newly created Swiss-based biopharmaceutical company, Idorsia Ltd.
The lenses adjust to sunlight and help eyes recover from bright light exposure faster. The lenses contain a photochromic additive that adapts visible light amounts filtered to the eyes and are the first to use such additives. In November , Biosense Webster, Inc.
In March , the company announced that LifeScan, Inc. Beckerle, D. Scott Davis, Ian E. Davis, Jennifer A. Doudna, Mark B.
McClellan, Anne M. Mulcahy, William D. Perez, Charles Prince, A. Eugene Washington, Marillyn A. Hewson and Ronald A.
Sandi Peterson has served as Group Worldwide Chairman since The company considered moving its headquarters out of New Brunswick in the s, but decided to stay in the town after city officials promised to revitalize downtown New Brunswick by demolishing old buildings and constructing new ones. While New Brunswick lost many historic structures, including the early home of Rutgers University, and most of its historic commercial waterfront to the redevelopment effort, the gentrification did attract people back to New Brunswick. Johnson and Johnson Plaza , in a park across the railroad tracks from the older portion of the headquarters, is one of tallest buildings in New Brunswick.
The stretch of Delaware and Raritan canal by the company's headquarters was replaced by a stretch of Route 18 in the late s,  after a lengthy dispute. The company's business is divided into three major segments, Pharmaceuticals, Medical Devices, and Consumer Products. In , these segments contributed The company's major franchises in the Pharmaceutical segment include Immunology, Neuroscience, Infectious Disease, and Oncology.
Immunology products include the anti- tumor necrosis factor antibodies Remicade infliximab , and Simponi golimumab used for the treatment  of autoimmune diseases, including rheumatoid arthritis , Crohn's disease Remicade only , ulcerative colitis , ankylosing spondylitis , and other disorders. A third immunology product, Stelara ustekinumab , targets interleukin and interleukin and is used for the treatment of psoriasis.
Invega Sustenna and Risperdal Consta were the first widely utilized long-acting depot injections for the treatment of schizophrenia. Designed to address the issue of poor patient compliance with oral therapy, they are administered by intramuscular injection at intervals of 2 weeks and one month, respectively.
Only minimal improvements in outcomes relative to the oral versions of these drugs were observed in the clinical trial setting, but some evidence suggests that the advantages of long-acting injections in clinical practice may be greater than is readily demonstrated in the environment of a clinical trial. Oncology products include Velcade bortezomib , for the treatment of multiple myeloma and mantle cell lymphoma  and Zytiga abiraterone , an androgen antagonist for the treatment of prostate cancer.
In clinical trials, abiraterone treatment was associated with a 4. In March the FDA approved esketamine for the treatment of severe depression,  which is marketed as Spravato by Janssen Pharmaceuticals. Sectors in which the company is active  include:.
Sectors in which the company is active  include:. On September 29, , a "Tylenol scare" began when the first of seven individuals died in Chicago metropolitan area , after ingesting Extra Strength Tylenol that had been deliberately laced with cyanide. The case remains unsolved and no suspects have been charged. The recall was conducted after a routine inspection at a manufacturing facility in Fort Washington, Pennsylvania , United States revealed that some "products may not fully meet the required manufacturing specifications".
Metal debris from wear of the implant led to a reaction that destroyed the soft tissues surrounding the joint, leaving some patients with long term disability. Ions of cobalt and chromium—the metals from which the implant was made—were also released into the blood and cerebral spinal fluid in some patients. In a group of shareholders sued the board for allegedly failing to take action to prevent serious failings and illegalities since the s, including manufacturing problems, bribing officials, covering up adverse effects and misleading marketing for unapproved uses. The judge initially dismissed the case in September , but allowed the plaintiffs opportunity to refile at a later time.
In , the United States Department of Justice joined a whistleblowers suit accusing the company of illegally marketing Risperdal through Omnicare , the largest company supplying pharmaceuticals to nursing homes. Food and Drug Administration FDA not to promote Risperdal as effective and safe for elderly patients, but they did so, and that they paid Omnicare to promote the drug to care home physicians. However, the emblem was not protected by U. A clause in this law now 18 U. A declaration made by the U.
In October , the company and its subsidiary, Ethicon, Inc. By March , over 1, U.